Literature DB >> 7355249

The new NCI screen and its implications for clinical evaluation.

A Goldin, J M Venditti.   

Abstract

Mesh：

Substances：

Year:  1980        PMID： 7355249     DOI： 10.1007/978-3-642-81392-4_2

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  3 in total

1.  Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Authors:  Brendan Murphy; Han Yin; John M Maris; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Stephen T Keir; Raushan T Kurmasheva; Igor Dvorchik; Jianrong Wu; Catherine A Billups; Nana Boateng; Malcolm A Smith; Richard B Lock; Peter J Houghton
Journal:  Cancer Res       Date:  2016-08-05       Impact factor: 12.701

2.  Preclinical antitumor activity of batracylin (NSC 320846).

Authors:  J Plowman; K D Paull; G Atassi; S D Harrison; D J Dykes; H J Kabbe; V L Narayanan; O C Yoder
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

3.  Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma.

Authors:  C Greco; G Zupi; G Badaracco
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.